SCHEMBL9607733

SCHEMBL9607733

Cc1ccc(-c2nc(C(C)(C)C)nc(Cl)c2OCc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 2/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
POLB P06746 1/20 0.36
CNR1 P21554 2/20 0.36
LMNA P02545 2/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607729 0.84 POLB (0.42) L3MBTL1HTTALDH1A1KDM4EMEN1
SCHEMBL6918467 0.81 CYP19A1 (0.39) CNR2L3MBTL1NPC1HTTALDH1A1
SCHEMBL1232782 0.79 HTT (0.42) L3MBTL1NPC1HTTALDH1A1KDM4E
SCHEMBL9607748 0.76 MEN1 (0.34) CNR2MEN1KMT2ANPSR1MAPT
SCHEMBL9607734 0.75 ALOX5 (0.46) L3MBTL1NPC1HTTALDH1A1KDM4E
SCHEMBL10763451 0.73 MAPT (0.42) L3MBTL1HTTMAPTTDP1LMNA
SCHEMBL9607720 0.71 LMNA (0.43) L3MBTL1HTTALDH1A1MAPTTDP1
SCHEMBL10698767 0.67 SOAT1 (0.49) CNR1
SCHEMBL1232578 0.66 KMO (0.46) NPC1HTTMAPTCNR1LMNA
SCHEMBL25465503 0.65 ALKBH1 (0.43) L3MBTL1HTTALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 CNR2 3332/4885L3MBTL1 4611/4885NPC1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.